title: Modulation of the axon-reflex response to local heat by reactive oxygen species in subjects with chronic fatigue syndrome.
abstract: Local cutaneous heating causes vasodilation as an initial first peak, a nadir, and increase to plateau. Reactive oxygen species (ROS) modulate the heat plateau in healthy controls. The initial peak, due to C-fiber nociceptor-mediated axon reflexes, is blunted with local anesthetics and may serve as a surrogate for the cutaneous response to peripheral heat. Chronic fatigue syndrome (CFS) subjects report increased perception of pain. To determine the role of ROS in this neurally mediated response, we evaluated changes in cutaneous blood flow from local heat in nine CFS subjects (16-22 yr) compared with eight healthy controls (18-26 yr). We heated skin to 42°C and measured local blood flow as a percentage of maximum cutaneous vascular conductance (%CVC(max)). Although CFS subjects had significantly lower baseline flow [8.75 ± 0.56 vs. 12.27 ± 1.07 (%CVC(max), CFS vs. control)], there were no differences between groups to local heat. We then remeasured this with apocynin to inhibit NADPH oxidase, allopurinol to inhibit xanthine oxidase, tempol to inhibit superoxide, and ebselen to reduce H(2)O(2). Apocynin significantly increased baseline blood flow (before heat, 14.91 ± 2.21 vs. 8.75 ± 1.66) and the first heat peak (69.33 ± 3.36 vs. 59.75 ± 2.75). Allopurinol and ebselen only enhanced the first heat peaks (71.55 ± 2.48 vs. 61.72 ± 2.01 and 76.55 ± 5.21 vs. 58.56 ± 3.66, respectively). Tempol had no effect on local heating. None of these agents changed the response to local heat in control subjects. Thus the response to heat may be altered by local levels of ROS, particularly H(2)O(2) in CFS subjects, and may be related to their hyperesthesia/hyperalgesia.
authors.affiliation: Department of Pediatrics, New York Medical College and The Center for Pediatric Hypotension, Hawthorne, New York 10532, USA. Marvin_Medow@NYMC.edu
authors.forename: Marvin S
authors.initials: MS
authors.lastname: Medow
authors.forename: Arun
authors.initials: A
authors.lastname: Aggarwal
authors.forename: Ila
authors.initials: I
authors.lastname: Baugham
authors.forename: Zachary
authors.initials: Z
authors.lastname: Messer
authors.forename: Julian M
authors.initials: JM
authors.lastname: Stewart
mesh_terms: D000098:Acetophenones / Q000494:pharmacology; D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000493:Allopurinol / Q000494:pharmacology; D000975:Antioxidants / Q000494:pharmacology; D001369:Axons / Q000378:metabolism / Q000502:physiology*; D003497:Cyclic N-Oxides / Q000494:pharmacology; D015673:Fatigue Syndrome, Chronic / Q000378:metabolism* / Q000503:physiopathology*; D005260:Female; D006358:Hot Temperature; D006801:Humans; D006861:Hydrogen Peroxide / Q000037:antagonists & inhibitors / Q000378:metabolism; D008297:Male; D019255:NADPH Oxidases / Q000037:antagonists & inhibitors / Q000378:metabolism; D036421:Nerve Fibers, Unmyelinated / Q000378:metabolism; D009619:Nociceptors / Q000378:metabolism; D010146:Pain / Q000378:metabolism / Q000503:physiopathology; D017382:Reactive Oxygen Species / Q000378:metabolism*; D012018:Reflex / Q000502:physiology*; D012039:Regional Blood Flow / Q000187:drug effects / Q000502:physiology; D012867:Skin / Q000098:blood supply / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D013113:Spin Labels; D013481:Superoxides / Q000037:antagonists & inhibitors; D014664:Vasodilation / Q000187:drug effects / Q000502:physiology; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors / Q000378:metabolism; D055815:Young Adult
chemical_list: D000098:Acetophenones; D000975:Antioxidants; D003497:Cyclic N-Oxides; D017382:Reactive Oxygen Species; D013113:Spin Labels; D013481:Superoxides; D000493:Allopurinol; C056165:acetovanillone; D006861:Hydrogen Peroxide; D014969:Xanthine Oxidase; D019255:NADPH Oxidases; C001803:tempol